Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.39 |
| ▸ | CES1 | P23141 | 3/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5706885 | 0.86 | P2RX7 (0.35) | CES2CES1ACHEP2RX7 | |
| SCHEMBL19682345 | 0.86 | ACHE (0.46) | CES2CES1ACHEP2RX7HTR2A | |
| SCHEMBL17471747 | 0.84 | CES2 (0.37) | CES2CES1HTR2CTDP1 | |
| SCHEMBL18242776 | 0.79 | CES2 (0.43) | CES2CES1ACHEMC4RHTR2A | |
| SCHEMBL31258568 | 0.78 | CES2 (0.41) | CES2CES1ACHEMC4RBCHE | |
| SCHEMBL807556 | 0.78 | CES2 (0.41) | CES2CES1ACHEMC4RHTR2A | |
| SCHEMBL18242026 | 0.75 | CES2 (0.41) | CES2CES1ACHEBCHEDRD2 | |
| SCHEMBL30662728 | 0.75 | — | — | |
| SCHEMBL22331223 | 0.75 | — | — | |
| SCHEMBL19682342 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4583876-A1 | COMBINATION OF A T CELL THERAPY AND CONTINUOUS OR INTERMITTENT DGK INHIBITOR DOSING | Juno Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| CN-120152717-A | Combination of T cell therapy and continuous or intermittent DGK inhibitor administration | 朱诺治疗学股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-112654621-B | Substituted naphthyridinone compounds useful as T cell activators | 百时美施贵宝公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240108654-A1 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | JUNO THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-11945806-B2 | Stabilization of amyloidogenic immunoglobulin light chains | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-02 | — | — | US | disclosed |
| WO-2024054944-A1 | COMBINATION OF A T CELL THERAPY AND CONTINUOUS OR INTERMITTENT DGK INHIBITOR DOSING | JUNO THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| CN-117693508-A | Combination of T cell therapy and DGK inhibitors | 朱诺治疗学股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-4301755-A1 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | Juno Therapeutics, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-3814348-B9 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3814348-B1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20080139390-A1 | Isoxazoline Derivatives and Their Use as Herbicides | SYNGENTA LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
| US-7378522-B2 | Such as 6-(4-Acetamidophenoxy)-5-(N-benzyl-N-methylaminomethyl)-1-(2',6'-difluorobenzyl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid-ethyl ester; rapid effectiveness, bioavailability; low cost, simple synthesis | ZENTARIS AG (DE) | 2008-05-27 | — | — | US | disclosed |
| US-20050004127-A1 | Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone | AETERNA ZENTARIS GMBH (DE) | 2005-01-06 | — | — | US | disclosed |
| US-6790858-B2 | HIGH EFFECTIVENESS AND HIGH ORAL BIOAVAILABILITY; FOR EXAMPLE, 6-(4-ACETAMIDOPHENYL)-3-ISOBUTYRYL-5-(N-BENZYL-N-METHYLAMINOMETHYL)-1-(2',6'-DIFLUOROBENZYL)-1,4-DIHYDRO-4-OXOQUINOLINE | ZENTARIS AG (DE) | 2004-09-14 | — | — | US | disclosed |
| EP-1362034-A1 | QUINOLINE, ISOQUINOLINE AND PHTHALAZINE DERIVATIVES AS ANTAGONISTS OF THE GONADOTROPIN-RELEASING HORMONE | Schering Aktiengesellschaft (DE) | 2003-11-19 | — | — | EP | disclosed |
| US-6613493-B2 | Formed by nitrating a polyvinylphenol or a novalak and reacting the the hydroxy group with with a halide comprising an acid labile protecting group, such as 2-(1-bromoethyl)-1,3-difluorobenzene | HYNIX SEMICONDUCTOR INC (KR) | 2003-09-02 | — | — | US | disclosed |
| US-20030105328-A1 | Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone | SCHERING AG (DE) | 2003-06-05 | — | — | US | disclosed |
| US-20030013036-A1 | Photoresist polymer and composition having nitro groups | HYNIX SEMICONDUCTOR INC. (KR) | 2003-01-16 | — | — | US | disclosed |
| WO-2002066437-A1 | QUINOLINE, ISOQUINOLINE AND PHTHALAZINE DERIVATIVES AS ANTAGONISTS OF THE GONADOTROPIN-RELEASING HORMONE | ZENTARIS GMBH (DE) | 2002-08-29 | — | — | WO | disclosed |
| US-4851424-A | 1-Phenyl-lower alkyl-imidazole 4- or 5-carboxamide compounds which are useful in the treatment of epilepsy | CIBA-GEIGY CORPORATION (US) | 1989-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004127-A1 | Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone | GNRHR, LHCGR, PRLHR | CES2 4544/4885CES1 4726/4885ACHE 2819/4885 |
| US-20080139390-A1 | Isoxazoline Derivatives and Their Use as Herbicides | MTX1, MTX2, CHRM1 | CES2 109/4885CES1 282/4885ACHE 113/4885 |
| US-20030105328-A1 | Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone | GNRHR, LHCGR, PRLHR | CES2 4544/4885CES1 4726/4885ACHE 2819/4885 |
| US-20240108654-A1 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | DGKG, DGKA, DGKI | CES2 2442/4885CES1 1019/4885ACHE 3607/4885 |
| US-11945806-B2 | Stabilization of amyloidogenic immunoglobulin light chains | TTR, MAP1LC3B, SAAL1 | CES2 3852/4885CES1 2104/4885ACHE 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.